| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/20/2009 | US20090209450 MicroRNA Fingerprints During Human Megakaryocytopoiesis |
| 08/20/2009 | US20090209041 Peptides and methods for inhibiting amyloid formation |
| 08/20/2009 | US20090209037 Viral core protein-cationic lipid-nucleic acid-delivery complexes |
| 08/20/2009 | US20090209034 Tumour rejection antigens |
| 08/20/2009 | US20090209006 Taci-immunoglobulin fusion proteins |
| 08/20/2009 | US20090208974 Human Neuronal Attachment Factor-1 |
| 08/20/2009 | US20090208972 Cytotoxic protein and utlization thereof |
| 08/20/2009 | US20090208969 Polynucleotides and Polypeptides Encoding Receptors |
| 08/20/2009 | US20090208967 Genetic Polymorphisms As Predictive Diagnostics For Adverse Drug Reactions (ADR) And Drug Efficacy |
| 08/20/2009 | US20090208938 Use of the MCM8 Gene for the Preparation of a Pharmaceutical Composition |
| 08/20/2009 | US20090208928 Method and device for the in vitro detection of polycystic ovarian syndrome (pcos) and pathologies involving cardiovascular risk |
| 08/20/2009 | US20090208589 Novel hydrophilic polymers as medical lubricants and gels |
| 08/20/2009 | US20090208581 Formulations limiting spread of pulmonary infections |
| 08/20/2009 | US20090208565 Stabilized exendin-4 compounds |
| 08/20/2009 | US20090208552 Cross-linked fatty acid-based biomaterials |
| 08/20/2009 | US20090208550 Methods and compositions for treating hepatic diseases |
| 08/20/2009 | US20090208537 Anti-Neovasculature Preparations for Cancer |
| 08/20/2009 | US20090208524 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| 08/20/2009 | US20090208521 Pharmaceutical compositions containing protein nma0939 |
| 08/20/2009 | US20090208518 Immunogenic peptides for the treatment of prostate and breast cancer |
| 08/20/2009 | US20090208512 Catalytic anti-factor VIII allo-antibodies |
| 08/20/2009 | US20090208511 Novel method for identifying diabetic patients at increased risk for pathological complications |
| 08/20/2009 | US20090208504 Polypeptides involved in immune response |
| 08/20/2009 | US20090208499 adminstering N-(phosphonomethyl)-proline free of N-(phosphonomethyl)-glycine or N,N-bis(phosphonomethyl)-glycine to a patient to treat cosmetic conditions and medical disorders, symptoms or syndromes associated with at least one of a nervous, vascular, musculoskeletal or cutaneous system |
| 08/20/2009 | US20090208493 Compounds and methods for the selective inhibition of ABCB1, ABCC1 and ABCG2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors |
| 08/20/2009 | US20090208484 R-spondin compositions and methods of use thereof |
| 08/20/2009 | US20090208482 Human obesity susceptibility gene encoding a member of the neurexin family and uses thereof |
| 08/20/2009 | US20090208481 Proteomic analysis of active multiple sclerosis lesions |
| 08/20/2009 | US20090208480 Long half-life recombinant butyrylcholinesterase |
| 08/20/2009 | US20090208479 Compositions and Methods for Effecting the Levels of High Density Lipoprotein (HDL) Cholesterol and Apolipoprotein AI, Very Low Density Lipoprotein (VLDL) Cholesterol and Low Density Lipoprotein (LDL) Cholesterol |
| 08/20/2009 | US20090208478 Transducible polypeptides for modifying metabolism |
| 08/20/2009 | US20090208477 Production of high mannose proteins in plant culture |
| 08/20/2009 | US20090208476 Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins |
| 08/20/2009 | US20090208475 Mina53 assays |
| 08/20/2009 | US20090208474 Biological entities and the use thereof |
| 08/20/2009 | US20090208473 Compositions and methods to modulate cell membrane resealing |
| 08/20/2009 | US20090208468 SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE |
| 08/20/2009 | US20090208459 Methods of treating anemia using recombinant adeno-associated virus virions |
| 08/20/2009 | US20090208458 Transcriptional inhibitor for human k-ras gene |
| 08/20/2009 | US20090208457 Tricyclic-Nucleoside Prodrugs for Treating Viral Infections |
| 08/20/2009 | US20090208456 Imidazo[4,5-d]pyrimidines, their uses and methods of preparation |
| 08/20/2009 | US20090208455 Method for Treating Polyglutamine Expansion Neurodegenerative Diseases |
| 08/20/2009 | US20090208454 Modified interferon beta polypeptides and their uses |
| 08/20/2009 | US20090208453 High pressure treatment of aggregated interferons |
| 08/20/2009 | US20090208452 Inhibitor of Endogenous Human Interferon-Gamma |
| 08/20/2009 | US20090208451 Halogen phosphonate monoesters |
| 08/20/2009 | US20090208450 Method for enhancing the efficacy of antigen specific tumor immunotherapy |
| 08/20/2009 | US20090208449 Heterocyclic antiviral compounds |
| 08/20/2009 | US20090208448 Inhibition of angiogenesis |
| 08/20/2009 | US20090208447 Polypeptides |
| 08/20/2009 | US20090208446 DUB3 as a Cancer Therapy Target |
| 08/20/2009 | US20090208440 Biological entities and the use thereof |
| 08/20/2009 | US20090208408 Use of vcam-1 ligands for detecting and/or treating cardiovascular diseases |
| 08/20/2009 | CA2747133A1 Uses of modified elr-cxc chemokine g31p |
| 08/20/2009 | CA2726861A1 Devices, formulations, and methods for delivery of multiple beneficial agents |
| 08/20/2009 | CA2723314A1 Templated open flocs of anisotropic particles for enhanced pulmonary delivery |
| 08/20/2009 | CA2718592A1 Method of treating vascular sclerosis |
| 08/20/2009 | CA2715517A1 Immunogenic peptides and their use in transplantation |
| 08/20/2009 | CA2715379A1 Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease |
| 08/20/2009 | CA2715294A1 Genetic regulation of host defense mechanisms by mucosal exposure to natural interferon alpha species |
| 08/20/2009 | CA2714445A1 Treatment of metastatic stage prostate cancer with degarelix |
| 08/20/2009 | CA2714444A1 Method of treating prostate cancer with the gnrh antagonist degarelix |
| 08/20/2009 | CA2714155A1 Fish protein hydrolysate having a bone-stimulating and -maintaining activity, nutraceutical and pharmacological compositions comprising such a hydrolysate and method for obtaining same |
| 08/20/2009 | CA2714128A1 Fish protein hydrolysate having a satietogenic activity, nutraceutical and pharmacological compositions comprising such a hydrolysate and method for obtaining same |
| 08/20/2009 | CA2705373A1 Hiv-1 envelope glycoprotein oligomer and methods of use |
| 08/19/2009 | EP2090657A2 Anti-IL-12 antibodies, compositions, methods and uses |
| 08/19/2009 | EP2090654A1 PARTIAL FRAGMENT OF REIC/Dkk-3 GENE AND THERAPEUTIC AGENT FOR CANCER CONTAINING THE SAME |
| 08/19/2009 | EP2090589A1 Albumin-fused Kunitz domain peptides |
| 08/19/2009 | EP2090583A1 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| 08/19/2009 | EP2090319A2 Angiotensin peptide-carrier conjugates and uses thereof |
| 08/19/2009 | EP2090317A1 Method of preventing or treating diabetes |
| 08/19/2009 | EP2089521A1 Soluble tnf receptors and their use in treatment of disease |
| 08/19/2009 | EP2089431A2 Methods and compositions for efficient removal of protein a from binding molecule preparations |
| 08/19/2009 | EP2089425A2 Anti-angiogenic compounds |
| 08/19/2009 | EP2089419A2 Inhibition of beta-amyloid aggregation |
| 08/19/2009 | EP2089417A2 Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
| 08/19/2009 | EP2089416A1 Depsipeptides and their therapeutic use |
| 08/19/2009 | EP2089415A1 Depsipeptides and their therapeutic use |
| 08/19/2009 | EP2089057A2 Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
| 08/19/2009 | EP2089050A2 Il- 17b for use in wound healing |
| 08/19/2009 | EP2089049A2 Systemic administration of colony stimulating factors to treat amyloid associated disorders |
| 08/19/2009 | EP2089048A2 Composition for cartilage |
| 08/19/2009 | EP2089047A2 Compositions and methods for cardiac tissue protection and regeneration |
| 08/19/2009 | EP2089046A2 Antidiabetogenic calcium-peptide composition |
| 08/19/2009 | EP2089045A2 Use of il-27 antagonists for the manufacture of a medicament for the treatment of aplastic anemia |
| 08/19/2009 | EP2089029A2 Pak modulators |
| 08/19/2009 | EP2089026A2 Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy |
| 08/19/2009 | EP2089008A2 Formulations for delivery via pressurised metered dose inhalers comprising an essential oil as suspension stabiliser |
| 08/19/2009 | EP1988917A4 Compositions and methods to enhance viability and function of islet cells |
| 08/19/2009 | EP1940877A4 Modified biodegradable polymers, preparation and use thereof for making biomaterials and dressings |
| 08/19/2009 | EP1824501B1 Protein hydrolysate with antidiabetic effect |
| 08/19/2009 | EP1814394A4 Use of antioxidants for gene modulation |
| 08/19/2009 | EP1776139A4 Targeting damaged lung tissue |
| 08/19/2009 | EP1725099A4 Peptide mixtures with immunomodulatory activity |
| 08/19/2009 | EP1691827B1 Use of peptides derived from the b beta chain of human fibronogen for the treatment of shock |
| 08/19/2009 | EP1576120B1 Bacillus subtilis for use against animal and human pathogens |
| 08/19/2009 | EP1566182A4 Antioxidant pharmaceutical compound, method for producing polypeptide and method of cure |
| 08/19/2009 | EP1562621B1 Composition for treating ichthyosis using antitrypsin |
| 08/19/2009 | EP1497467B1 Oligonucleotides from sequences coding for the surface component of ptlv envelope proteins and uses thereof |
| 08/19/2009 | EP1389941B1 Alleviation of the memory deficits and memory components of psychiatric dysfunctions by altering atypical pkm activity |